SCHEMBL13147146

SCHEMBL13147146

N=C(NCCCCN1CCCC1)NC(=O)c1cccc(Cl)c1CCc1cc(Br)cc2ccoc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 3/20 0.40
▸ DRD3 P35462 8/20 0.39
▸ DRD2 P14416 7/20 0.39
▸ DRD4 P21917 7/20 0.39
▸ SIGMAR1 Q99720 2/20 0.37
▸ SMYD2 Q9NRG4 1/20 0.36
▸ HRH4 Q9H3N8 1/20 0.36
▸ FPR3 P25089 3/20 0.36
▸ FPR2 P25090 3/20 0.36
▸ PHF13 Q86YI8 1/20 0.35
▸ L3MBTL3 Q96JM7 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ HTR1A P08908 2/20 0.34
▸ DRD1 P21728 2/20 0.34
▸ HTR2A P28223 2/20 0.34
▸ HTR2C P28335 2/20 0.34
▸ HTR2B P41595 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13147330 0.91 MC4R (0.49) MC4RFPR3FPR2PHF13L3MBTL3
SCHEMBL13147083 0.90 MC4R (0.48) MC4RFPR3FPR2PHF13L3MBTL3
SCHEMBL13147091 0.90 MC4R (0.49) MC4RFPR3FPR2PHF13L3MBTL3
SCHEMBL13147357 0.84 MC4R (0.45) MC4RDRD3DRD2DRD4HTR1A
SCHEMBL13147119 0.83 ALDH1A1 (0.45) MC4RL3MBTL1
SCHEMBL13147075 0.82 MC4R (0.59) MC4RDRD3DRD2DRD4SIGMAR1
SCHEMBL14193795 0.80 MC4R (0.43) MC4RDRD3DRD2DRD4SMYD2
SCHEMBL13147074 0.79 MC4R (0.58) MC4RDRD3DRD2DRD4SIGMAR1
SCHEMBL13147168 0.79 CHRM1 (0.42) MC4R
SCHEMBL13147102 0.75 MC4R (0.51) MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790719-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS, INC. (US) 2010-09-07 — — US disclosed
US-7790719-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS, INC. (US) 2010-09-07 — — US disclosed
US-7365070-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS INC. (US) 2008-04-29 — — US disclosed
US-7365070-B2 Modulators of melanocortin receptor ORE PHARMACEUTICALS INC. (US) 2008-04-29 — — US disclosed
US-20070293498-A1 Modulators of melanocortin receptor GENE LOGIC, INC. (US) 2007-12-20 — — US disclosed
US-20070293498-A1 Modulators of melanocortin receptor GENE LOGIC, INC. (US) 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293498-A1 Modulators of melanocortin receptor MC4R, MC1R, MC5R MC4R 1/4885DRD3 316/4885DRD2 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback